Page 21 - பல்கலைக்கழகம் ஆஃப் கலிஃபோர்னியா இல் சான் பிரான்சிஸ்கோ News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The controversial approval of an Alzheimer’s drug reignites the battle over the underlying cause of the disease Laurie McGinley © Jessica Rinaldi/Pool/Via Reuters Marc Archambault, who has early-stage Alzheimer s disease, receives his first dose Wednesday of the newly approved intravenous drug Aduhelm at Butler Hospital in Providence, R.I. (Jessica Rinaldi/Pool/Reuters) Neurologist Matthew S. Schrag was surprised when he heard the Food and Drug Administration had approved a controversial Alzheimer’s drug. There was scant evidence the treatment worked, in his view. Even more concerning to Schrag: the FDA’s apparent embrace of a long-debated theory about Alzheimer’s disease, which afflicts more than 6 million Americans. The amyloid hypothesis, which has dominated the field for decades, holds that toxic clumps in the brain, called amyloid beta, are the main driver of the disease and that removing them will slow cognitive decline.

University of southern californiaUnited statesRhode islandGil rabinoviciPeter steinDennis gibbsJanet woodcockVanderbilt schragEli lillyAlfred sandrock jrMarc archambaultMatthews schragHalima amjadJason karlawishPaula newhouseAlois alzheimer